Allogeneic cell therapies are on the cusp of a transformative breakthrough, fueled by promising clinical data and compelling long-term trends. As the field advances towards large-scale commercialization, a critical focal point emerges: the optimization of downstream processes. These processes encompass the intricate art of efficient cell harvesting, as well as the seamless orchestration of drug product preparation involving complex steps such as formulation, filling, labeling, and inspection.
This presentation and Q&A will cover lessons learned from commercialized autologous cell therapies, highlight key differences between one-to-one vs. one-to-many cell therapies, and profile automation and closed processing technologies optimized for allogeneic cell therapies.
Attendees will learn: